COFEPRIS & MFDS: A New 30-Day Fast-Track for Korean MedTech in Mexico

This episode explores the transformative Abbreviated Regulatory Pathway being launched by Mexico's COFEPRIS in September 2025. We detail how this new 30-day process specifically benefits Korean medical device manufacturers holding MFDS approval, outlining the immense opportunity for accelerated market entry. The discussion also covers critical challenges, such as proving product equivalency and navigating submission requirements, to help companies leverage this shortcut effectively. - What is Mexico's new Abbreviated Regulatory Pathway for medical devices? - When does the new COFEPRIS 30-day approval process take effect? - How can Korean companies leverage their existing MFDS approval for faster market access in Mexico? - What are the key requirements for proving product equivalency between Korean and Mexican submissions? - How can you avoid common pitfalls when using this new expedited pathway? - What does this regulatory change mean for the Latin American MedTech market? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies seeking to accelerate global market entry. Our experts specialize in developing efficient regulatory strategies, like leveraging Mexico's new 30-day abbreviated pathway for MFDS-approved devices. We act as your local representative in over 30 markets, using advanced AI to compile and submit technical dossiers that minimize rejections. Whether you are a startup or a multinational, Pure Global provides the local expertise and technology-driven solutions needed to navigate complex regulatory environments. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.